Peter R. Galle, MD, PhD - Assembling a Long-Term Sequential Plan for Unresectable HCC: Practical Guidance for Improving Real-World Outcomes

episode

CME in Minutes: Education in Oncology & Hematology not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

Transrapid, Flugtaxis, Hyperloop – Warum es neuartige Verkehrstechnik so schwer hat 28 min · 22 Sep 2026 · Das Wissen | SWR

Las 10 de Erazno, el Chokolatazo, Parodias, Nacadas y mas 1h 25m · 22 Sep 2026 · Erazno y La Chokolata El Podcast

Cross-code immorality, Lachie Neale's strike, crowd behaviour - Andrew Voss | Across the Divide! (22.09.26) 17 min · 22 Sep 2026 · Whateley

S13 EP19: It's Exhausting Having an Opinion 37 min · 22 Sep 2026 · Parenting Hell with Rob Beckett and Josh Widdicombe

Fall in Love With the Life You Have 51 min · 22 Sep 2026 · The Candace Cameron Bure Podcast

NPR News: 09-21-2026 9PM EDT 5 min · 22 Sep 2026 · NPR News Now

Report any issue

Source

Recorded10 Jan 2024

Publisherc.answersincme.com ↗

Handlerec:766053

Show notes

Please visit answersincme.com/EFR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in liver disease discusses management of unresectable hepatocellular carcinoma through multiple lines of therapy. Upon completion of this activity, participants should be better able to: Identify clinical signs of progression on treatment for unresectable hepatocellular carcinoma (HCC) to enhance timely use of a sequential therapy; Describe the clinical impact of tyrosine kinase inhibitors for the real-world treatment of unresectable HCC; and Outline real-world clinical strategies to maximize the long-term treatment plan for patients with unresectable HCC through multiple lines of therapy.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in